---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-000184"
form_type: "8-K"
ticker: "BPTH"
cik: "0001133818"
company_name: "BIO-PATH HOLDINGS, INC."
filed_at: "2024-01-10T23:59:59+00:00"
generated_at: "2026-06-07T00:51:56.697142+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bio-Path completes first dose cohort in Phase 1 trial of BP1002 for lymphoma/CLL

## Summary
- BP1002, a liposomal Bcl-2 antisense, advanced to next dose cohort (40 mg/m²) after completing 20 mg/m² cohort safely.
- Trial targets refractory/relapsed lymphoma and CLL patients, including those who failed venetoclax-based therapy.
- Phase 1 uses 3+3 design; six evaluable patients per cohort; enrollment open for second cohort.
- BP1002 targets Bcl-2 mRNA, potentially overcoming BH3 domain mutations causing venetoclax resistance.

## SEC filing metadata
- accession: 0001558370-24-000184
- form_type: 8-K
- ticker: BPTH
- cik: 0001133818
- company_name: BIO-PATH HOLDINGS, INC.
- filed_at: 2024-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133818/000155837024000184/0001558370-24-000184-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133818/000155837024000184/bpth-20240110x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-000184
- JSON: https://secwatch.observer/filing/0001558370-24-000184.json
- Plain text: https://secwatch.observer/filing/0001558370-24-000184.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.